Skip to main content

Search

Astellas Pharma Inc.

Our use of cookies

We use strictly necessary cookies to make our site work. We would also like to set optional performance & analytics cookies to help us improve it. We will not set optional cookies unless you enable them. Using this tool will set a cookie on your device to remember your preferences.

For more detailed information about the cookies we use, see our Cookies page

Strictly necessary cookies
Always On

Strictly necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions. These cookies do not store any information that directly identifies you.

Performance & Analytics cookies

Performance cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. The information collected by these cookies is used to create aggregated, anonymous analytics reports. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

  • About
    • Philosophy
    • Vision & Strategy
    • Group Code of Conduct
    • Astellas Pharma Israel
    • Policies & Position Statements
  • Therapy Areas
    • Therapy Areas
      • Urology
      • Oncology / Haematology
    • Astellas Products
      • ELIGARD™ (leuprorelin acetate)
      • BETMIGA™ (mirabegron)
      • DIFICLIR™ (fidaxomicin)
      • MYCAMINE™ (micafungin sodium)
      • RIBOMUSTIN™ (bendamustine)
      • XTANDI™ (enzalutamide)
  • Innovation
    • R & D
      • Clinical Trials
      • Approach
      • Ethics & Principles
    • Pipeline
    • Investigator Sponsored Research
    Recommended
    Clinical Trials

    Astellas has established a website to disclose information obtained from Astellas-sponsored clinical trials…

    Read More
  • Responsibility
    • Making an Impact
      • Environment
      • CSR-Based Management
        • ISO26000
        • Materiality
      • Access to Health
      • Ethics & Compliance
        • Transparency
          • Supporting-patients
        • Modern Slavery Act
        • Gender Pay Gap Report
    Recommended
    Access to Health

    Advances continue to be made in technology and medicine that address unmet medical needs. However, there still remain barriers for many people…

    Read More
  • News
    • News
    • Media Contacts
    • Social Media Code of Conduct
    Recommended
    Media Contacts

    The Astellas Corporate Communications team will respond to calls and emails from journalists. For general media enquiries, please email contact_uk...

    Read More

Common header menu

  • CONTACT US
  • CAREERS
  • WORLDWIDE
  • ISRAEL
  • WORLDWIDE - ISRAEL
  • English
  • עברית
Latest Pause Next
Astellas Pharma Israel
Astellas Pharma Israel
Find out more
Urology
Urology
Find out more
Oncology / Haematology
Oncology / Haematology
Find out more
1
2
3
  • Making an Impact

    Making an Impact
    Find out more
  • Therapy Areas

    Therapy Areas
    Find out more

NON_2020_0015_IL

LogoSolgan

Follow us on social media

linkedin_icon twitter_icon

Bottom footer menu

  • SITE MAP
  • PRIVACY NOTICE
  • TERMS OF USE
  • COOKIES POLICY
© 2020 Astellas Pharma Inc.